I85PREP
⌘ K
CPGP study materials
CPGP study resources

CPGP practice questions

One question at a time. Build your CPGP understanding.

First 50 of 190 questions. Each one lists the choices, the correct answer, and an explanation. The checker at the top of this page saves progress in this browser when it is available.

Continue in the practice tool above to load more questions, 50 at a time.

Question 1Product, process, validation and quality systems

Which FDA regulation specifically establishes current Good Manufacturing Practice (cGMP) requirements for finished pharmaceutical products?

  1. 21 CFR Part 11
  2. 21 CFR Part 211 Correct answer.
  3. 21 CFR Part 820
  4. 21 CFR Part 111

Explanation

21 CFR Part 211 establishes the cGMP regulations for finished pharmaceutical products, covering all aspects from organization and personnel to buildings, equipment, production, and laboratory controls. Part 11 covers electronic records, Part 820 covers medical device quality systems, and Part 111 covers dietary supplements. Exam tip: Know the scope of Parts 210 (general) and 211 (specific) and how they differ from other FDA cGMP regulations.

Question 2Product, process, validation and quality systems

What is the relationship between 21 CFR Part 210 and 21 CFR Part 211?

  1. Part 210 applies to APIs and Part 211 to finished dosage forms
  2. Part 210 provides general cGMP definitions and Part 211 provides specific requirements for finished pharmaceuticals Correct answer.
  3. Part 210 covers laboratory controls and Part 211 covers production controls
  4. Part 210 is voluntary guidance and Part 211 is legally enforceable

Explanation

21 CFR Part 210 establishes general cGMP definitions and applicability provisions, while Part 211 provides the specific, detailed requirements for manufacturing, processing, packing, and holding finished pharmaceutical products. Both parts are legally enforceable regulations. Exam tip: Part 210 sets the foundation; Part 211 builds the detailed framework. Both are binding law, not guidance.

Question 3Product, process, validation and quality systems

ICH Q7 provides GMP guidance for which specific category of pharmaceutical materials?

  1. Finished dosage forms
  2. Excipients
  3. Packaging materials
  4. Active Pharmaceutical Ingredients (APIs) Correct answer.

Explanation

ICH Q7 ('Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients') specifically provides GMP guidance for the manufacture of APIs used in human medicinal products. It covers production, quality control, and quality management for API manufacturing. Exam tip: ICH Q7 is the go-to reference for API GMP - remember the 'Q' series focuses on quality topics.

Question 4Product, process, validation and quality systems

Which EU GMP Annex addresses the manufacture of sterile medicinal products?

  1. Annex 1 Correct answer.
  2. Annex 15
  3. Annex 11
  4. Annex 13

Explanation

EU GMP Annex 1 covers the manufacture of sterile medicinal products and was significantly revised in 2022 with an effective date of August 2023. It addresses contamination control strategy, cleanroom classification, environmental monitoring, and aseptic processing. Exam tip: The revised Annex 1 introduced the Contamination Control Strategy (CCS) concept - a frequent exam topic.

Question 5Product, process, validation and quality systems

Under 21 CFR Part 211, which role is responsible for approving or rejecting all procedures and specifications affecting the identity, strength, quality, and purity of a drug product?

  1. Production manager
  2. Regulatory affairs director
  3. Quality control unit Correct answer.
  4. Plant manager

Explanation

21 CFR 211.22 assigns the quality control unit the authority and responsibility to approve or reject all procedures or specifications impacting product identity, strength, quality, and purity. This includes reviewing and approving production and control procedures, sampling plans, and specifications. Exam tip: The QC unit's independence and authority under 211.22 is a cornerstone of US cGMP - expect questions on its specific responsibilities.

Question 6Product, process, validation and quality systems

Which WHO document provides the primary GMP guidelines for pharmaceutical products?

  1. WHO Essential Medicines List
  2. WHO Prequalification Programme Standards
  3. WHO Technical Report Series No. 986, Annex 2 Correct answer.
  4. WHO Pharmacopoeia Guidelines

Explanation

The WHO GMP guidelines for pharmaceutical products are published as annexes to the WHO Technical Report Series (TRS). TRS No. 986, Annex 2 is a key revision of WHO GMP guidelines covering quality management, personnel, premises, equipment, and documentation. Exam tip: WHO GMP is especially relevant for manufacturers supplying to countries that rely on WHO prequalification rather than FDA/EMA approval.

Question 7Product, process, validation and quality systems

A pharmaceutical company manufactures products for both the US and EU markets. During an FDA inspection, the investigator cites a deviation. The company argues the practice complies with EU GMP. How should this situation be handled?

  1. The company must comply with FDA requirements for products intended for the US market Correct answer.
  2. The company must comply with whichever regulation is more stringent
  3. EU GMP compliance is sufficient since regulations are harmonized
  4. ICH guidelines supersede both FDA and EU requirements

Explanation

When manufacturing for the US market, FDA cGMP requirements (21 CFR Parts 210/211) apply regardless of compliance with other regulatory frameworks. While EU GMP and FDA cGMP share many principles, specific requirements can differ, and each regulator enforces its own standards. Exam tip: For multi-market manufacturers, the practical approach is to comply with the most stringent requirement across all target markets, but legally each regulator enforces its own rules.

Question 8Product, process, validation and quality systems

ICH Q1A(R2) provides guidance on which pharmaceutical topic?

  1. Process validation
  2. Pharmaceutical quality systems
  3. Stability testing of new drug substances and products Correct answer.
  4. Impurity testing in drug substances

Explanation

ICH Q1A(R2) is the guideline on 'Stability Testing of New Drug Substances and Products,' establishing principles for generating stability data required for registration applications. It defines storage conditions, testing frequency, and data evaluation requirements. Exam tip: The ICH Q1 family covers stability (Q1A–Q1F). Remember Q1A for general principles, Q1B for photostability, Q1E for data evaluation.

Question 9Product, process, validation and quality systems

Under FDA's data integrity guidance, which acronym represents the principles that all cGMP data must satisfy?

  1. ALCOA+ Correct answer.
  2. SMART
  3. PDCA
  4. DMAIC

Explanation

ALCOA+ stands for Attributable, Legible, Contemporaneous, Original, Accurate, plus Complete, Consistent, Enduring, and Available. These principles define data integrity expectations under cGMP for all data, whether electronic or paper. Exam tip: ALCOA+ is a universal data integrity framework referenced by FDA, WHO, PIC/S, and MHRA - know all nine elements and be able to identify violations.

Question 10Product, process, validation and quality systems

Which FDA regulation specifically addresses requirements for electronic records and electronic signatures in pharmaceutical manufacturing?

  1. 21 CFR Part 210
  2. 21 CFR Part 58
  3. 21 CFR Part 820
  4. 21 CFR Part 11 Correct answer.

Explanation

21 CFR Part 11 establishes criteria under which FDA considers electronic records and electronic signatures to be trustworthy, reliable, and equivalent to paper records and handwritten signatures. It addresses validation, audit trails, access controls, and signature manifestations. Exam tip: Part 11 applies to any electronic records required by predicate rules - pair it with data integrity (ALCOA+) for a complete understanding.

Question 11Product, process, validation and quality systems

A pharmaceutical manufacturer receives a Form 483 from an FDA investigator. What does this document represent?

  1. An official approval of the facility's GMP compliance
  2. A mandatory product recall order
  3. A list of inspectional observations of conditions that may constitute violations of the FD&C Act Correct answer.
  4. A warning letter requiring immediate facility shutdown

Explanation

FDA Form 483 is issued at the conclusion of an inspection and lists the investigator's observations of conditions that may violate the Federal Food, Drug, and Cosmetic Act. It is not a final determination of violation but gives the company an opportunity to respond. Exam tip: The escalation path is 483 → Warning Letter → Consent Decree → Injunction. Companies typically have 15 business days to respond to a 483.

Question 12Product, process, validation and quality systems

Which ICH guideline specifically addresses pharmaceutical development, including Quality by Design (QbD) principles?

  1. ICH Q8(R2) Correct answer.
  2. ICH Q10
  3. ICH Q7
  4. ICH Q2(R2)

Explanation

ICH Q8(R2) 'Pharmaceutical Development' introduces Quality by Design (QbD) concepts including the design space, quality target product profile (QTPP), critical quality attributes (CQAs), and risk-based approaches to development. It complements Q9 (risk management) and Q10 (quality systems). Exam tip: Q8-Q9-Q10 form the 'quality trilogy' - Q8 for development, Q9 for risk, Q10 for quality system lifecycle.

Question 13Product, process, validation and quality systems

Under PIC/S, what is the primary purpose of the Pharmaceutical Inspection Co-operation Scheme?

  1. To manufacture pharmaceutical products across member countries
  2. To approve new drug applications on behalf of member states
  3. To harmonize GMP inspection standards and promote mutual recognition among regulatory authorities Correct answer.
  4. To set pricing standards for pharmaceutical products globally

Explanation

PIC/S (Pharmaceutical Inspection Co-operation Scheme) aims to harmonize GMP inspection practices and promote international cooperation among regulatory authorities. It facilitates the exchange of information and mutual confidence in GMP inspections. Exam tip: PIC/S is an inspectorate-focused organization - it harmonizes how inspections are done, not what regulations say.

Question 14Product, process, validation and quality systems

Which section of 21 CFR Part 211 requires that laboratory records include complete data derived from all tests performed to ensure compliance with established specifications?

  1. 211.68 - Automatic, mechanical, and electronic equipment
  2. 211.160 - General requirements for laboratory controls
  3. 211.194 - Laboratory records Correct answer.
  4. 211.188 - Batch production and control records

Explanation

21 CFR 211.194 specifically requires laboratory records to include complete data derived from all tests, examinations, and assays, including graphs, charts, and spectra from laboratory instrumentation, properly identified to show the specific component, batch, or product tested. Exam tip: 211.194 vs 211.160 - 194 covers record content, 160 covers general laboratory requirements including scientifically sound specifications.

Question 15Product, process, validation and quality systems

According to FDA guidance, what is the difference between a 'deviation' and a 'nonconformance' in pharmaceutical manufacturing?

  1. A deviation is unplanned; a nonconformance is a planned change
  2. They are identical terms used interchangeably in FDA regulations
  3. A deviation is a departure from an approved instruction or established standard; a nonconformance is when a product or material fails to meet specifications Correct answer.
  4. A deviation applies only to APIs; a nonconformance applies only to finished products

Explanation

A deviation refers to a departure from an approved procedure, process, or established standard, while a nonconformance specifically refers to a product, material, or result that fails to meet established acceptance criteria or specifications. Both require investigation, but the corrective actions differ. Exam tip: Deviations are process-focused (what went wrong in the process), while nonconformances are product/result-focused (the output failed to meet specifications).

Question 16Product, process, validation and quality systems

EU GMP Annex 11 provides requirements for which area of pharmaceutical manufacturing?

  1. Biological medicinal products
  2. Computerised systems Correct answer.
  3. Parametric release
  4. Qualification and validation

Explanation

EU GMP Annex 11 specifically addresses computerised systems used in pharmaceutical manufacturing, covering risk management, validation, security, data integrity, and electronic signatures. It parallels FDA 21 CFR Part 11 but with additional GMP-specific requirements. Exam tip: Annex 11 (EU) and Part 11 (FDA) both deal with electronic systems but are not identical - know the key differences, especially around risk-based approaches.

Question 17Product, process, validation and quality systems

Which ICH guideline establishes the framework for quality risk management in the pharmaceutical industry?

  1. ICH Q8(R2)
  2. ICH Q9(R1) Correct answer.
  3. ICH Q10
  4. ICH Q12

Explanation

ICH Q9(R1) 'Quality Risk Management' provides a systematic framework for assessing, controlling, communicating, and reviewing risks to quality throughout the product lifecycle. It describes tools such as FMEA, HACCP, FTA, and risk ranking. Exam tip: Q9(R1) was revised in 2023 to strengthen formality and decision-making - know the two core principles: risk evaluation should be science-based, and the level of effort should be commensurate with the level of risk.

Question 18Product, process, validation and quality systems

Under 21 CFR Part 211, what is the minimum frequency for calibration of laboratory instruments?

  1. Monthly
  2. Quarterly
  3. Annually
  4. At suitable intervals as established by written procedures Correct answer.

Explanation

21 CFR 211.68 and 211.160 require that instruments be calibrated at suitable intervals according to an established written program with specific directions, schedules, and limits for accuracy and precision. The regulation does not prescribe a fixed frequency but requires scientifically justified intervals. Exam tip: FDA regulations often use 'suitable' or 'appropriate' rather than fixed intervals - the company must justify its chosen frequency through risk assessment and instrument performance history.

Question 19Product, process, validation and quality systems

Which FDA enforcement action is typically issued after a company fails to adequately address Form 483 observations?

  1. Consent decree
  2. Warning letter Correct answer.
  3. Import alert
  4. Product seizure

Explanation

A Warning Letter is the typical next step when a company's response to a Form 483 is inadequate or when the observations constitute significant violations. It formally notifies the company that FDA considers them in violation of the FD&C Act and expects corrective action. Exam tip: The typical FDA enforcement escalation is: EIR → 483 → Warning Letter → Consent Decree/Injunction. Warning letters are public and can significantly impact a company's reputation.

Question 20Product, process, validation and quality systems

According to ICH Q10, what is the primary objective of a Pharmaceutical Quality System (PQS)?

  1. To reduce manufacturing costs through process efficiency
  2. To achieve product realisation and establish and maintain a state of control, and to facilitate continual improvement Correct answer.
  3. To ensure compliance with only FDA regulations
  4. To automate all manufacturing processes

Explanation

ICH Q10 defines the PQS objectives as achieving product realisation (providing products with appropriate quality attributes), establishing and maintaining a state of control, and facilitating continual improvement. These objectives apply across the entire product lifecycle. Exam tip: ICH Q10 extends beyond GMP compliance - it's a lifecycle approach. Remember the three objectives and the four PQS elements: process performance and product quality monitoring, CAPA, change management, and management review.

Question 21Product, process, validation and quality systems

What are the four elements of the Pharmaceutical Quality System as defined by ICH Q10?

  1. Process performance and product quality monitoring, CAPA, change management, management review Correct answer.
  2. Plan, do, check, act
  3. Design, develop, validate, verify
  4. Risk assessment, risk control, risk communication, risk review

Explanation

ICH Q10 identifies four PQS elements: (1) process performance and product quality monitoring, (2) corrective action and preventive action (CAPA), (3) change management, and (4) management review. These elements operate throughout the product lifecycle. Exam tip: PDCA is a general quality cycle; the Q10 four elements are pharmaceutical-specific. Don't confuse Q10 PQS elements with Q9 risk management steps.

Question 22Product, process, validation and quality systems

In a CAPA system, what distinguishes a 'corrective action' from a 'preventive action'?

  1. Corrective actions are documented; preventive actions are not
  2. Corrective actions address identified nonconformities; preventive actions address potential nonconformities before they occur Correct answer.
  3. Corrective actions are mandatory; preventive actions are optional under cGMP
  4. Corrective actions apply to equipment; preventive actions apply to personnel

Explanation

Corrective actions are taken to eliminate the cause of an existing nonconformity or undesirable situation, while preventive actions are taken to eliminate the cause of a potential nonconformity or other potentially undesirable situation. Both are required elements of an effective quality system. Exam tip: Think of it this way - corrective = reactive (something happened), preventive = proactive (prevent it from ever happening). Both require root cause analysis.

Question 23Product, process, validation and quality systems

Which root cause analysis tool uses a fishbone-shaped diagram to categorize potential causes of a problem?

  1. Fault Tree Analysis (FTA)
  2. Pareto chart
  3. Failure Mode and Effects Analysis (FMEA)
  4. Ishikawa (fishbone) diagram Correct answer.

Explanation

The Ishikawa diagram (also called a fishbone or cause-and-effect diagram) organizes potential causes into categories (typically the 6 Ms: Man, Machine, Material, Method, Measurement, Mother Nature) to systematically identify root causes. It is a visual brainstorming tool. Exam tip: Ishikawa is for brainstorming potential causes; FMEA quantifies risk through severity, occurrence, and detection ratings; FTA uses Boolean logic for complex failure scenarios.

Question 24Product, process, validation and quality systems

A pharmaceutical company implements a change to its tablet compression parameters. According to ICH Q10 change management principles, which step must occur BEFORE implementing the change?

  1. Post-implementation review
  2. Revalidation of the entire manufacturing process
  3. Notification to the FDA
  4. Risk assessment of the proposed change and approval by the quality unit Correct answer.

Explanation

ICH Q10 requires that proposed changes be evaluated using quality risk management to determine the potential impact on product quality before implementation. The quality unit must approve changes based on this assessment. Not all changes require FDA notification or full revalidation. Exam tip: The change control sequence is: initiate → risk assess → evaluate impact → approve → implement → verify effectiveness. Risk assessment determines the level of qualification/validation needed.

Question 25Product, process, validation and quality systems

What is the primary purpose of management review in a Pharmaceutical Quality System?

  1. To approve individual batch records for release
  2. To assess the suitability, adequacy, and effectiveness of the quality system and identify improvement opportunities Correct answer.
  3. To conduct routine laboratory testing
  4. To train new employees on SOPs

Explanation

Management review, as defined in ICH Q10, is a periodic evaluation by senior management to assess the overall performance and effectiveness of the PQS, including CAPA trending, process performance, product quality, and regulatory changes. It drives continual improvement. Exam tip: Management review is a senior leadership responsibility - it looks at trends and system-level performance, not individual batch decisions.

Question 26Product, process, validation and quality systems

In a pharmaceutical CAPA investigation, what is the most critical step after identifying the root cause?

  1. Closing the CAPA record
  2. Notifying regulatory authorities
  3. Assigning a due date
  4. Implementing corrective and preventive actions and verifying their effectiveness Correct answer.

Explanation

After root cause identification, the most critical step is implementing appropriate corrective and preventive actions and then verifying their effectiveness through defined metrics. Without effectiveness verification, there is no assurance the actions actually resolved the issue. Exam tip: A CAPA is not complete until effectiveness is verified - many FDA 483 observations cite 'failure to verify effectiveness of corrective actions.'

Question 27Product, process, validation and quality systems

What does FMEA stand for and what does it quantify?

  1. Facility Management and Environmental Assessment - quantifies environmental impact
  2. Failure Mode and Effects Analysis - quantifies risk using severity, occurrence, and detection Correct answer.
  3. Final Manufacturing Evaluation and Approval - quantifies batch acceptability
  4. Functional Method Equivalency Assessment - quantifies analytical method similarity

Explanation

Failure Mode and Effects Analysis (FMEA) is a systematic risk assessment tool that identifies potential failure modes, their causes and effects, and quantifies risk using three factors: severity (impact), occurrence (likelihood), and detection (ability to detect before impact). The product of these scores gives the Risk Priority Number (RPN). Exam tip: RPN = Severity × Occurrence × Detection. High RPN items get priority for risk mitigation. FMEA is referenced in ICH Q9 as a key risk assessment tool.

Question 28Product, process, validation and quality systems

A pharmaceutical company identifies a recurring deviation in its blending process. Three separate investigations have found different root causes each time. What is the most appropriate quality system response?

  1. Continue investigating each deviation individually
  2. Increase in-process testing frequency without investigating further
  3. Accept the deviations as inherent process variability
  4. Conduct a trending analysis and systemic root cause investigation to identify the common underlying cause Correct answer.

Explanation

Recurring deviations with different apparent root causes suggest a systemic issue that individual investigations failed to identify. A trending analysis and systemic investigation should examine common factors across all occurrences to find the true underlying cause. Exam tip: Trending is a requirement of ICH Q10 - if you see the same type of deviation recurring, the quality system should escalate to a broader investigation rather than treating each as isolated.

Question 29Product, process, validation and quality systems

According to ICH Q10, during which stages of the product lifecycle does the Pharmaceutical Quality System apply?

  1. Only during commercial manufacturing
  2. Throughout the entire product lifecycle: development, technology transfer, commercial manufacturing, and product discontinuation Correct answer.
  3. Only during development and manufacturing
  4. Only during regulatory submission and post-approval

Explanation

ICH Q10 applies the PQS across all four lifecycle stages: pharmaceutical development, technology transfer, commercial manufacturing, and product discontinuation. This lifecycle approach ensures quality is built in from development and maintained through the product's entire life. Exam tip: The lifecycle concept is central to ICH Q10 - each stage has specific PQS activities. Technology transfer is often overlooked but is critical for maintaining quality when moving between sites.

Question 30Product, process, validation and quality systems

What is the purpose of a Corrective Action Preventive Action (CAPA) effectiveness check?

  1. To verify that the implemented actions actually resolved the identified problem and prevented recurrence Correct answer.
  2. To determine if the CAPA was completed on time
  3. To ensure CAPA documentation is filed correctly
  4. To satisfy an audit requirement only

Explanation

A CAPA effectiveness check verifies that the implemented corrective and preventive actions actually achieved their intended result - the problem is resolved, and recurrence is prevented. This typically involves monitoring relevant metrics over a defined period after implementation. Exam tip: Effectiveness checks should be objective and measurable - not just 'no recurrence observed' but defined criteria with a timeframe. FDA commonly cites lack of effectiveness verification.

Question 31Product, process, validation and quality systems

A quality risk management exercise yields a residual risk that is above the acceptable threshold but below the initial risk level. What is the appropriate next step per ICH Q9?

  1. Accept the risk since it has been reduced
  2. Re-evaluate the risk control measures and determine if additional mitigation is needed or if the residual risk can be accepted with justification Correct answer.
  3. Immediately stop the process
  4. Submit a regulatory variation

Explanation

Per ICH Q9, if residual risk remains above the acceptance threshold after implementing risk controls, the organization must either implement additional controls to further reduce risk or formally evaluate and justify acceptance of the residual risk with appropriate documentation and stakeholder communication. Exam tip: Risk acceptance must be documented and justified - 'we reduced it somewhat' is not sufficient if it remains above the acceptance criteria.

Question 32Product, process, validation and quality systems

In a pharmaceutical quality system, what is the purpose of a document change control system?

  1. To prevent any changes to approved documents
  2. To maintain a library of obsolete documents
  3. To ensure that changes to controlled documents are reviewed, approved, and communicated before implementation Correct answer.
  4. To transfer documents between departments

Explanation

A document change control system ensures that proposed changes to controlled documents (SOPs, specifications, batch records) are properly reviewed for impact, approved by authorized personnel, and communicated to affected users before implementation. This prevents unauthorized or unevaluated changes. Exam tip: Document control is a cGMP fundamental - 21 CFR 211.22 requires quality unit approval of all procedures affecting product quality. Effective dates, training, and superseded version control are key elements.

Question 33Product, process, validation and quality systems

Which quality system tool is most appropriate for prioritizing which CAPAs to address first when resources are limited?

  1. Control chart
  2. Process flow diagram
  3. Risk matrix or risk ranking Correct answer.
  4. Scatter plot

Explanation

A risk matrix or risk ranking tool evaluates CAPAs based on severity and probability to prioritize those with the highest potential impact on patient safety and product quality. This risk-based approach to prioritization is consistent with ICH Q9 principles. Exam tip: When the exam presents a resource allocation scenario, think risk-based prioritization - ICH Q9 explicitly supports using risk assessment to determine where to focus quality system efforts.

Question 34Product, process, validation and quality systems

A company's Annual Product Review (APR) reveals an increasing trend in assay results approaching the upper specification limit over 12 months. What quality system action is most appropriate?

  1. No action needed since results are within specification
  2. Widen the specification limits
  3. Initiate an investigation and evaluate the need for CAPA to address the trend before an out-of-specification result occurs Correct answer.
  4. Reduce testing frequency to minimize data points

Explanation

An upward trend approaching the specification limit, even with results still within spec, is an Out-of-Trend (OOT) concern that warrants investigation and potential preventive action. The APR is specifically designed to detect such trends. Waiting until an OOS occurs is reactive and may impact product quality. Exam tip: APR/PQR trending is a proactive quality system tool - it should detect adverse trends before OOS results occur. This is preventive action in its truest form.

Question 35Product, process, validation and quality systems

What is the primary purpose of a supplier qualification program in a pharmaceutical quality system?

  1. To negotiate lower prices with suppliers
  2. To ensure that suppliers can consistently provide materials and services that meet predetermined quality requirements Correct answer.
  3. To maintain a list of backup suppliers
  4. To comply with import regulations only

Explanation

A supplier qualification program evaluates and approves suppliers based on their ability to consistently provide materials and services meeting quality requirements. This includes auditing, testing, evaluating quality systems, and ongoing monitoring. It is a cGMP requirement and a key element of ICH Q10. Exam tip: Supplier qualification is risk-based - the level of qualification activity should be proportional to the risk the material poses to product quality (e.g., APIs require more scrutiny than packaging components).

Question 36Product, process, validation and quality systems

According to ICH Q10, what is 'knowledge management' in the context of pharmaceutical quality?

  1. A training records management system
  2. A database of regulatory submissions
  3. An inventory of intellectual property
  4. A systematic approach to acquiring, analyzing, storing, and disseminating product and process knowledge throughout the lifecycle Correct answer.

Explanation

ICH Q10 defines knowledge management as a systematic approach to acquiring, analyzing, storing, and disseminating information about products, manufacturing processes, and components. It is an enabler of the PQS that supports science-based decision making. Exam tip: Knowledge management and quality risk management are the two 'enablers' of the PQS in ICH Q10. Knowledge should flow from development through commercialization and back.

Question 37Product, process, validation and quality systems

A pharmaceutical company is evaluating a proposed change to switch a critical raw material supplier. Which quality system elements must be involved?

  1. Only purchasing and logistics
  2. Only the quality control laboratory
  3. Change control, supplier qualification, risk assessment, and regulatory evaluation Correct answer.
  4. Only regulatory affairs for filing a supplement

Explanation

Switching a critical raw material supplier requires a comprehensive approach: change control to manage the process, supplier qualification to assess the new supplier, risk assessment to evaluate impact on product quality, and regulatory evaluation to determine if a regulatory filing is needed. Multiple quality system elements work together. Exam tip: Supplier changes for critical materials are high-risk changes - they typically require comparative testing, stability studies, and potentially regulatory notification depending on the material and market.

Question 38Product, process, validation and quality systems

What is the key difference between a planned deviation and an unplanned deviation?

  1. Planned deviations require approval; unplanned do not
  2. Unplanned deviations are always more severe
  3. Planned deviations never require investigation
  4. A planned deviation is a pre-approved, temporary departure from a procedure; an unplanned deviation is an unexpected departure discovered during or after the event Correct answer.

Explanation

A planned deviation is a pre-approved, documented temporary departure from an established procedure (e.g., processing a batch with a different equipment train due to maintenance), while an unplanned deviation is an unexpected departure discovered during or after the event. Both require documentation, but planned deviations include prospective risk assessment. Exam tip: Planned deviations must be risk-assessed and quality-approved BEFORE execution. If it wasn't pre-approved, it's unplanned regardless of intent.

Question 39Product, process, validation and quality systems

In the context of ICH Q10, what does 'continual improvement' mean for a pharmaceutical quality system?

  1. Ongoing activities to enhance the ability to fulfill quality requirements by identifying and implementing improvements based on PQS performance data Correct answer.
  2. Making changes to products only when FDA requires them
  3. Replacing equipment on a fixed schedule
  4. Increasing production volume each year

Explanation

ICH Q10 defines continual improvement as ongoing activities driven by PQS performance data - including CAPA trending, APR/PQR outcomes, audit findings, and management review outputs - to enhance quality system effectiveness and product quality. It is proactive, not reactive. Exam tip: Continual improvement is not just fixing problems - it means proactively using data to identify improvement opportunities. The PQS should generate the data that drives these improvements.

Question 40Product, process, validation and quality systems

What is the primary purpose of maintaining positive pressure differentials between cleanroom areas in a pharmaceutical facility?

  1. To improve worker comfort
  2. To prevent contamination from flowing into cleaner areas when doors are opened Correct answer.
  3. To reduce energy costs
  4. To maintain constant temperature

Explanation

Positive pressure differentials (typically 10-15 Pa between cleanroom grades) ensure that air flows from cleaner to less clean areas, preventing particulate and microbial contamination from entering critical manufacturing zones when doors are opened or through any gaps. Exam tip: The rule is 'air flows from clean to dirty.' For potent compound handling, this is reversed (containment) - a common exam scenario asking about pressure differential direction.

Question 41Product, process, validation and quality systems

During IQ/OQ/PQ of a pharmaceutical HVAC system, which qualification stage verifies that the system operates correctly under normal production conditions with product present?

  1. Design Qualification (DQ)
  2. Performance Qualification (PQ) Correct answer.
  3. Operational Qualification (OQ)
  4. Installation Qualification (IQ)

Explanation

Performance Qualification (PQ) verifies that equipment or systems perform consistently and reproducibly under actual or simulated production conditions, including with product and operators present. IQ verifies installation per design, and OQ verifies operation within specified parameters without product. Exam tip: IQ = installed correctly, OQ = operates correctly within parameters, PQ = performs consistently under real conditions. Know the distinction between 'at rest' (OQ) and 'in operation' (PQ).

Question 42Product, process, validation and quality systems

A pharmaceutical facility is designing a water system to produce Water for Injection (WFI). Under current FDA and EU requirements, which methods are acceptable for WFI generation?

  1. Distillation or reverse osmosis with appropriate validated purification steps Correct answer.
  2. Distillation only
  3. Any filtration method that produces water meeting WFI specifications
  4. Deionization alone

Explanation

The revised EU Pharmacopoeia (and FDA long-standing position) now allows WFI production by distillation or by other purification methods equivalent to distillation, such as reverse osmosis combined with electrodeionization and ultrafiltration, provided the water meets WFI specifications. Previously, EU required distillation only. Exam tip: The EU changed its WFI requirements in 2017 to allow non-distillation methods - this harmonized with USP, which has accepted RO-based WFI for longer.

Question 43Product, process, validation and quality systems

What is the primary purpose of an environmental monitoring program in a pharmaceutical cleanroom?

  1. To determine if the HVAC system is energy efficient
  2. To measure employee productivity
  3. To demonstrate ongoing control of the manufacturing environment by monitoring viable and non-viable particulate contamination Correct answer.
  4. To ensure raw materials meet specifications

Explanation

An environmental monitoring (EM) program systematically monitors viable (microbial) and non-viable (particulate) contamination levels in the manufacturing environment to demonstrate that the facility remains in a state of control. Alert and action limits trigger investigations when trends indicate a loss of control. Exam tip: EM programs must include defined sampling locations, frequencies, alert/action limits, and trending - all validated and based on risk assessment. Recovery plans must be documented.

Question 44Product, process, validation and quality systems

A pharmaceutical company is designing a multi-product oral solid dosage facility. What is the most critical contamination control consideration?

  1. Maximizing production throughput
  2. Minimizing the number of cleanrooms
  3. Preventing cross-contamination between different products through dedicated or validated cleaning procedures, airlock design, and pressure cascades Correct answer.
  4. Using the same equipment for all products to reduce costs

Explanation

In multi-product facilities, cross-contamination prevention is the most critical design consideration. This requires dedicated equipment where risk warrants it, validated cleaning procedures with scientifically justified acceptance limits, appropriate airlocks, pressure cascades, and potentially campaign manufacturing approaches. Exam tip: Cross-contamination risk assessment should consider potency, toxicity, and shared equipment surfaces. Health-based exposure limits (HBELs) per EMA guidance are now the standard for cleaning validation acceptance criteria.

Question 45Product, process, validation and quality systems

What is the purpose of a Contamination Control Strategy (CCS) as introduced in the revised EU GMP Annex 1?

  1. To document the cleaning schedule for the facility
  2. To replace the need for environmental monitoring
  3. To provide a holistic, lifecycle approach identifying and mitigating all potential sources of contamination using current process and product understanding Correct answer.
  4. To define personnel gowning requirements only

Explanation

The Contamination Control Strategy (CCS), introduced in the revised EU GMP Annex 1, is a planned set of controls derived from current understanding that ensures fitness for purpose of the process and product quality. It is a holistic, site-wide document that identifies all contamination risks and the controls in place to mitigate them. Exam tip: CCS is a living document that integrates EM data, facility design, gowning, process controls, and utilities into one coherent strategy. It replaces the fragmented approach of addressing contamination risks in separate documents.

Question 46Product, process, validation and quality systems

During HVAC qualification of a pharmaceutical manufacturing area, what parameter is measured to confirm unidirectional airflow in a Grade A zone?

  1. Air velocity and airflow visualization (smoke studies) Correct answer.
  2. Temperature uniformity
  3. Relative humidity
  4. Sound level

Explanation

Unidirectional (laminar) airflow in Grade A zones is verified by measuring air velocity (typically 0.36-0.54 m/s per EU GMP Annex 1) and performing airflow visualization studies using smoke or aerosol to confirm that air sweeps contaminants away from the critical zone without turbulence or dead spots. Exam tip: Smoke studies are a visual qualification tool - they must demonstrate that unidirectional flow is maintained even during operator interventions. Video documentation is best practice.

Question 47Product, process, validation and quality systems

What is the typical pressure differential maintained between adjacent cleanroom grades in a pharmaceutical facility?

  1. 5 Pa (0.02 inches WG)
  2. 100 Pa (0.40 inches WG)
  3. 50 Pa (0.20 inches WG)
  4. 10-15 Pa (0.04-0.06 inches WG) Correct answer.

Explanation

A pressure differential of 10-15 Pa (0.04-0.06 inches water gauge) between adjacent cleanroom grades is the industry standard recommended by EU GMP Annex 1 and ISO 14644. This provides adequate airflow to prevent contamination ingress while being manageable for door operation. Exam tip: Below 10 Pa may not prevent contamination during door opening; above 15 Pa can cause difficulty opening doors and excessive air turbulence. Continuous monitoring with alarms is expected.

Question 48Product, process, validation and quality systems

A pharmaceutical company is qualifying a new steam sterilizer (autoclave). Which validation approach sequence should be followed?

  1. PQ → OQ → IQ → DQ
  2. DQ → IQ → OQ → PQ Correct answer.
  3. OQ → IQ → PQ → DQ
  4. IQ → PQ → OQ → DQ

Explanation

The correct sequence for equipment qualification is DQ (Design Qualification) → IQ (Installation Qualification) → OQ (Operational Qualification) → PQ (Performance Qualification). Each stage must be completed satisfactorily before proceeding to the next. DQ confirms the design meets requirements, IQ verifies installation, OQ verifies operation, and PQ confirms consistent performance. Exam tip: The V-model follows this sequence. Never skip stages - each builds on the previous one. Temperature mapping and biological indicator studies are key PQ activities for autoclaves.

Question 49Product, process, validation and quality systems

What is the most significant risk with pharmaceutical compressed air systems that are used in direct product contact applications?

  1. Oil, moisture, and microbial contamination of the product Correct answer.
  2. Excessive noise levels
  3. High energy consumption
  4. Equipment vibration

Explanation

Compressed air in direct product contact applications poses risks of oil contamination (from compressor lubricants), moisture (promoting microbial growth), and microbial contamination. These can directly affect product quality and patient safety. Compressed air must be qualified to appropriate ISO 8573 standards. Exam tip: Product-contact compressed air typically requires oil-free compressors or validated oil removal, HEPA/point-of-use filtration, and dew point monitoring. Classify air quality per ISO 8573 based on the application risk.

Question 50Product, process, validation and quality systems

In cleanroom gowning procedures, what is the correct order for donning sterile garments when entering a Grade B area?

  1. Gloves → gown → hood → boots → goggles
  2. Lab coat → hairnet → shoe covers
  3. Shoe covers → hood → coverall → face mask → sterile gloves (with sanitization steps between each) Correct answer.
  4. Any order as long as all garments are worn

Explanation

Proper gowning sequence for aseptic areas follows a top-down, outside-in principle: shoe covers, then hood/head cover, then coverall/suit, then face mask, and finally sterile gloves - with hand sanitization between critical steps. The sequence prevents contamination of clean garments by dirty surfaces. Exam tip: Gowning qualification is a cGMP requirement - personnel must demonstrate they can gown without contaminating the sterile garments. Media fill programs include gowning as part of the aseptic process simulation.